Edwards Lifesciences announced that the randomized PARTNER II Trial comparing the SAPIEN XT valve to surgery in intermediate-risk patients successfully...
Edwards Lifesciences has announced FDA approval to expand use of the Edwards Sapien XT transcatheter heart valve for pulmonic valve...
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
The FDA has approved an expanded indication for the Sapien XT and Sapien 3 transcatheter heart valves, from Edwards LifeSciences...
Medtronic has announced new data supporting the clinical and economic value of its cardiac resynchronization therapy (CRT) devices: Viva XT...